<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1130-6343</journal-id>
<journal-title><![CDATA[Farmacia Hospitalaria]]></journal-title>
<abbrev-journal-title><![CDATA[Farm Hosp.]]></abbrev-journal-title>
<issn>1130-6343</issn>
<publisher>
<publisher-name><![CDATA[Grupo Aula Médica]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1130-63432019000200053</article-id>
<article-id pub-id-type="doi">10.7399/fh.11111</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Analysis of acenocoumarol and levofloxacin interaction in elderly institutionalized patients]]></article-title>
<article-title xml:lang="es"><![CDATA[Análisis de la interacción de acenocumarol y levofloxacino en ancianos institucionalizados]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Taberner-Bonastre]]></surname>
<given-names><![CDATA[Pilar]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Moreno-Miralles]]></surname>
<given-names><![CDATA[Ana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Quintana-Vargas]]></surname>
<given-names><![CDATA[Isabel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Peris-Martí]]></surname>
<given-names><![CDATA[Juan Francisco]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Universitario Santa María Servicio de Farmacia Hospitalaria ]]></institution>
<addr-line><![CDATA[Lleida ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Residencia para Personas Mayores Dependientes La Cañada Servicio de Farmacia Hospitalaria ]]></institution>
<addr-line><![CDATA[Paterna Valencia]]></addr-line>
<country>Spain</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2019</year>
</pub-date>
<volume>43</volume>
<numero>2</numero>
<fpage>53</fpage>
<lpage>55</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1130-63432019000200053&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1130-63432019000200053&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1130-63432019000200053&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective: To analyze the interaction between acenocoumarol and levofloxacin in the elderly. We also assessed how hypoalbuminemia affects international normalized ratio variation.  Method: Retrospective study carried on elderly institutionalized patients who were prescribed levofloxacin concomitantly with acenocoumarol. International normalized ratio variation during levofloxacin treatment was analyzed with the t-Student test. Correlation between albuminemia and international normalized ratio variation was calculated using Pearson´s correlation coefficient.  Results: The mean international normalized ratio previous to treatment with levofloxacin was 2.5 (standard deviation: 0.6) and during treatment it was 4.7 (standard deviation: 1.9) (p &lt; 0.05). In 54.3% of the cases, the international normalized ratio value was equal to or greater than 4.5. Not linear association between albuminemia and international normalized ratio increase was found using Pearson´s test (R = -0.16).  Conclusions: In more than half of the occasions international normalized ratio raised to clinically rellevant values (&#8805; 4.5). No influence of hypoalbuminemia in the increase in international normalized ratio was shown.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo: Analizar la interacción levofloxacino-acenocumarol en ancianos y determinar la influencia de la hipoalbuminemia en el incremento del international normalized ratio.  Método: Estudio observacional retrospectivo en ancianos institucionalizados que recibieron simultáneamente acenocumarol y levofloxacino. Se analizó la variación del international normalized ratio durante el tratamiento con levofloxacino mediante la prueba t-Student. Se estudió la relación entre la albuminemia y la variación del international normalized ratio mediante el coeficiente de correlación de Pearson.  Resultados: La media de international normalized ratio previa al tratamiento con levofloxacino fue de 2,5 (desviación estándar 0,6) y durante el tratamiento fue de 4,7 (desviación estándar 1,9) (p &lt; 0,05). En el 54,3% de los casos el valor de international normalized ratio fue igual o superior a 4,5. La prueba de Pearson no mostró asociación lineal entre la albuminemia y el incremento de international normalized ratio (R = -0,16).  Conclusiones: En más de la mitad de las ocasiones, el international normalized ratio alcanzó valores de relevancia clínica (&#8805; 4,5). No se evidenció influencia de la hipoalbuminemia en el incremento del international normalized ratio.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Acenocoumarol]]></kwd>
<kwd lng="en"><![CDATA[Elderly]]></kwd>
<kwd lng="en"><![CDATA[Interaction]]></kwd>
<kwd lng="en"><![CDATA[Levofloxacin]]></kwd>
<kwd lng="en"><![CDATA[Nursing home]]></kwd>
<kwd lng="es"><![CDATA[Acenocumarol]]></kwd>
<kwd lng="es"><![CDATA[Ancianos]]></kwd>
<kwd lng="es"><![CDATA[Interacción]]></kwd>
<kwd lng="es"><![CDATA[Levofloxacino]]></kwd>
<kwd lng="es"><![CDATA[Sociosanitario]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="book">
<collab>Agencia Española de Medicamentos y Productos Sanitarios. Centro información online de medicamentos (CIMA)</collab>
<source><![CDATA[Ficha técnica del medicamento: Sintrom® (web page)]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Agencia Española de Medicamentos y Productos Sanitarios]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gschwind]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Rollason]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Lovis]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Boehlen]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Bonnabry]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Dayer]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Identification and weighting of the most critical &#8220;real-life&#8221; drug-drug interactions with acenocoumarol in a tertiary care hospital]]></article-title>
<source><![CDATA[Eur J Clin Pharmacol]]></source>
<year>2013</year>
<volume>69</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>617-27</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Palareti]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Leali]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Coccheri]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Poggi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Manotti]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[D&#8217;Angelo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT)]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1996</year>
<volume>348</volume>
<numero>9025</numero>
<issue>9025</issue>
<page-range>423-8</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stockley]]></surname>
<given-names><![CDATA[IH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anticoagulant drug interactions]]></article-title>
<source><![CDATA[Stockley´s drug interactions]]></source>
<year>2002</year>
<edition>6th</edition>
<page-range>288-9</page-range><publisher-loc><![CDATA[London ]]></publisher-loc>
<publisher-name><![CDATA[Pharmaceutical Press]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rehulková]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Interactions of warfarin]]></article-title>
<source><![CDATA[Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub]]></source>
<year>2001</year>
<numero>2</numero>
<issue>2</issue>
<page-range>27-38</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
<name>
<surname><![CDATA[Fugate]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Levofloxacin and warfarin interaction]]></article-title>
<source><![CDATA[Ann Pharmacother]]></source>
<year>2002</year>
<volume>36</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1554-7</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ravnan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Locke]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Levofloxacin and warfarin interaction]]></article-title>
<source><![CDATA[Pharmacotherapy]]></source>
<year>2001</year>
<volume>21</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>884-5</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Palacios-Zabalza]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Bustos-Martínez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Peral-Aguirregoitia]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Bengoechea]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Aguirre Gómez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Probable interaction between acenocoumarol and levofloxacin: a case series]]></article-title>
<source><![CDATA[J Clin Pharm Ther]]></source>
<year>2015</year>
<volume>40</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>693-5</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Palareti]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Cosmi]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bleeding with anticoagulation therapy - Who is at risk, and how best to identify such patients]]></article-title>
<source><![CDATA[Thromb Haemost]]></source>
<year>2009</year>
<volume>102</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>268-78</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grandinson]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
<name>
<surname><![CDATA[Boudinot]]></surname>
<given-names><![CDATA[FD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Age-related changes in protein binding of drugs: implications for therapy]]></article-title>
<source><![CDATA[Clin Pharmacokinet]]></source>
<year>2000</year>
<volume>38</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>271-90</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Horn]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Hansten]]></surname>
<given-names><![CDATA[PD]]></given-names>
</name>
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[LN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Proposal for a new tool to evaluate drug interaction cases]]></article-title>
<source><![CDATA[Ann Pharmacother]]></source>
<year>2007</year>
<volume>41</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>674-80</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mercadal Orfila]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Gracia García]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Leiva Badosa]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Perayre Badía]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Reynaldo Martínez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Jodar Masanés]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Retrospective assessment of potential interaction between levofloxacin and warfarin]]></article-title>
<source><![CDATA[Pharm World Sci]]></source>
<year>2009</year>
<volume>31</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>224-9</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tincani]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Mazzali]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Morini]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypoalbuminemia as a risk factor for over-anticoagulation]]></article-title>
<source><![CDATA[Am J Med]]></source>
<year>2002</year>
<volume>112</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>247-8</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mesa Urdinola]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Hipoalbuminemia como factor asociado con sobreanticoagulación por warfarina durante los primeros 4 días de tratamiento en pacientes mayores de 60 años. (Master&#8217;s Thesis)]]></source>
<year>2013</year>
<publisher-loc><![CDATA[Bogotá ]]></publisher-loc>
<publisher-name><![CDATA[Pontificia Universidad Javeriana]]></publisher-name>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
